137 related articles for article (PubMed ID: 38306130)
1. Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis.
Ziolkowska-Banasik D; Hadas E; Pastuszczak M
J Drugs Dermatol; 2024 Feb; 23(2):74-77. PubMed ID: 38306130
[TBL] [Abstract][Full Text] [Related]
2. Predicting Secukinumab Fast-Responder Profile in Psoriatic Patients: Advanced Application of Artificial-Neural-Networks (ANNs).
Damiani G; Conic RRZ; Pigatto PDM; Carrera CG; Franchi C; Cattaneo A; Malagoli P; Uppala R; Linder D; Bragazzi NL; Grossi E
J Drugs Dermatol; 2020 Dec; 19(12):1241-1246. PubMed ID: 33346505
[TBL] [Abstract][Full Text] [Related]
3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
4. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Kokolakis G; Warren RB; Strober B; Blauvelt A; Puig L; Morita A; Gooderham M; Körber A; Vanvoorden V; Wang M; de Cuyper D; Madden C; Nunez Gomez N; Lebwohl M
Br J Dermatol; 2023 Feb; 188(3):330-340. PubMed ID: 36751950
[TBL] [Abstract][Full Text] [Related]
5. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D
Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
[TBL] [Abstract][Full Text] [Related]
9. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
[TBL] [Abstract][Full Text] [Related]
10. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study.
Chiricozzi A; Balato A; Conrad C; Conti A; Dapavo P; Ferreira P; Gaiani FM; Leite L; Malagoli P; Mendes-Bastos P; Megna M; Messina F; Nidegger A; Odorici G; Panduri S; Piaserico S; Piscitelli L; Prignano F; Ribero S; Valerio J; Torres T
J Dermatolog Treat; 2020 Aug; 31(5):476-483. PubMed ID: 31557063
[No Abstract] [Full Text] [Related]
12. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.
Chicharro P; Llamas-Velasco M; Armesto S; Herrera Acosta E; Vidal D; Vilarrasa E; Rivera-Diaz R; De-la-Cueva P; Martorell-Calatayud A; Ballescà F; Belinchon I; Carretero G; Rodriguez L; Romero-Maté A; Pujol-Montcusí J; Salgado L; Sahuquillo-Torralba A; Coto-Segura P; Baniandrés Rodríguez O; Feltes R; Riera-Monroig J; Dauden E
Dermatol Ther; 2022 Dec; 35(12):e15929. PubMed ID: 36223184
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.
Costanzo A; Russo F; Galluzzo M; Stingeni L; Scuderi R; Zichichi L; Papini M; Di Costanzo L; Conti A; Burlando M; Chiricozzi A; Gaiani FM; Mugheddu C; Musumeci ML; Gisondi P; Piaserico S; Dapavo P; Venturini M; Pagnanelli G; Amerio P; Potenza C; Peris K; Cantoresi F; Trevisini S; Loconsole F; Offidani A; Mercuri SR; Lora V; Prignano F; Bartezaghi M; Oliva G; Aloisi E; Orsenigo R
Acta Derm Venereol; 2021 Oct; 101(10):adv00576. PubMed ID: 33903916
[TBL] [Abstract][Full Text] [Related]
14. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register.
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
JAMA Dermatol; 2021 Jan; 157(1):66-73. PubMed ID: 33263718
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study.
Wu NL; Hsu CJ; Sun FJ; Tsai TF
J Dermatol; 2017 Oct; 44(10):1129-1137. PubMed ID: 28493369
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.
Reich K; Körber A; Mrowietz U; Sticherling M; Sieder C; Früh J; Bachhuber T
Br J Dermatol; 2021 May; 184(5):849-856. PubMed ID: 32652528
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Langley RG; Sofen H; Dei-Cas I; Reich K; Sigurgeirsson B; Warren RB; Paul C; Szepietowski JC; Tsai TF; Hampele I; You R; Charef P; Papavassilis C
Br J Dermatol; 2023 Feb; 188(2):198-207. PubMed ID: 36763857
[TBL] [Abstract][Full Text] [Related]
18. Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis.
Papp KA; Lebwohl MG
J Drugs Dermatol; 2018 Mar; 17(3):247-250. PubMed ID: 29537442
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study).
Foley P; Manuelpillai N; Dolianitis C; Cains GD; Mate E; Tronnberg R; Baker C
Australas J Dermatol; 2022 Aug; 63(3):303-311. PubMed ID: 35809080
[TBL] [Abstract][Full Text] [Related]
20. Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study.
Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
Acta Derm Venereol; 2021 Jan; 101(1):adv00357. PubMed ID: 33320277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
